15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Dare Bioscience Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $10.00 sits 1118% above the current $0.82. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Dare Bioscience Inc.
As of Aug, 2 of 2 firms rate DARE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DARE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.30 – $-0.16 · 3 analysts · +132% YoY
Next period, 3 analysts expect Dare Bioscience Inc to earn $-0.23 a share (range $-0.30 – $-0.16), versus $-0.10 a year earlier. Full-year consensus is $-0.77, growing to $-0.41 the year after.
REVENUE · NEXT QUARTER
$359.3K
Range $0 – $898.0K · 3 analysts · -65% YoY
Revenue is expected to reach $359.3K (range $0 – $898.0K), -64.9% year-over-year. Full-year consensus is $2.7M, rising to $8.9M next year.
Top analysts covering Dare Bioscience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DARE.
#1
Douglas Tsao
HC Wainwright & Co. · Rank #245
Buy
$12.00+1361.5% to target
Overall win rate
35%
+ Follow
#2
CP
Caroline Palomeque
Maxim Group
Buy
$8.00+874.3% to target
Coverage
—
+ Follow
#3
KD
Kemp Dolliver
Brookline Capital Markets
Buy
$11.00+1239.7% to target
Coverage
—
+ Follow
DARE stock forecast FAQ
What is DARE's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Dare Bioscience Inc over the next 12 months, ranging from a $12.00 high to a $8.00 low.
Is DARE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DARE?+
The Street-high target is $12.00 (HC Wainwright & Co.), and the Street-low is $8.00 (Maxim Group). The average of all 2 active targets is $10.00.
How many Wall Street analysts cover DARE?+
2 analysts have an active rating on Dare Bioscience Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering DARE?+
Among analysts who currently cover DARE, Douglas Tsao of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #245). Their current call is Buy with a $12.00 target.
What is Dare Bioscience Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.30 – $-0.16) across 3 analysts. Full-year EPS is projected at $-0.77, rising to $-0.41 the following year.
How much revenue is Dare Bioscience Inc expected to report next quarter?+
Consensus revenue is $359.3K (range $0 – $898.0K). Full-year revenue is projected at $2.7M, growing to $8.9M next year.
Have analysts been upgrading or downgrading DARE lately?+
As of Aug, 2 of 2 firms rate DARE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DARE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
